- Home
- ANAB vs OFIX Comparison
ANAB vs OFIX Comparison
Compare ANAB & OFIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- OFIX
- Stock Information
- Founded
- ANAB 2005
- OFIX 1987
- Country
- ANAB United States
- OFIX United States
- Employees
- ANAB N/A
- OFIX N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- OFIX Medical/Dental Instruments
- Sector
- ANAB Health Care
- OFIX Health Care
- Exchange
- ANAB Nasdaq
- OFIX Nasdaq
- Market Cap
- ANAB 630.2M
- OFIX 562.8M
- IPO Year
- ANAB 2017
- OFIX N/A
- Fundamental
- Price
- ANAB $20.16
- OFIX $14.75
- Analyst Decision
- ANAB Buy
- OFIX Strong Buy
- Analyst Count
- ANAB 10
- OFIX 5
- Target Price
- ANAB $48.00
- OFIX $21.50
- AVG Volume (30 Days)
- ANAB 427.6K
- OFIX 427.7K
- Earning Date
- ANAB 11-04-2025
- OFIX 11-06-2025
- Dividend Yield
- ANAB N/A
- OFIX N/A
- EPS Growth
- ANAB N/A
- OFIX N/A
- EPS
- ANAB N/A
- OFIX N/A
- Revenue
- ANAB $123,164,000.00
- OFIX $809,030,000.00
- Revenue This Year
- ANAB $11.40
- OFIX $3.86
- Revenue Next Year
- ANAB $8.17
- OFIX $5.57
- P/E Ratio
- ANAB N/A
- OFIX N/A
- Revenue Growth
- ANAB 304.17
- OFIX 4.84
- 52 Week Low
- ANAB $12.21
- OFIX $10.24
- 52 Week High
- ANAB $40.55
- OFIX $20.73
- Technical
- Relative Strength Index (RSI)
- ANAB 41.04
- OFIX 61.38
- Support Level
- ANAB $20.61
- OFIX $14.21
- Resistance Level
- ANAB $23.64
- OFIX $15.42
- Average True Range (ATR)
- ANAB 1.22
- OFIX 0.45
- MACD
- ANAB 0.23
- OFIX -0.11
- Stochastic Oscillator
- ANAB 10.92
- OFIX 44.63
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About OFIX Orthofix Medical Inc. (DE)
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two main segments: global spine, including bone growth and healing therapies, spinal implants, and regenerative tissue products; and global orthopedics, providing products used in fracture repair, deformity correction, and bone reconstruction procedures. The majority of the company's sales come from the global spine segment in the United States. Orthofix distributes its products throughout North America, Europe, and several countries across the globe. The company provides solutions to hospitals, physicians, other healthcare providers, and patients.